{"id":"W3031022693","doi":"10.1200/jco.2020.38.15_suppl.1097","title":"Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative g<i>BRCA</i>-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Internal medicine; Hazard ratio; Veliparib; PARP inhibitor; Breast cancer; Progression-free survival; Oncology; Carboplatin; Biomarker; Cancer; Gastroenterology; Confidence interval; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001056258,0.0005525545,0.001286759,0.0002715634,0.0002240608,0.0008383137,0.0004480932,0.0006251441,0.002501593],"category_scores_gemma":[0.000965094,0.0002862044,0.00116722,0.0003735555,0.0004758965,0.0006687706,0.0003206909,0.001426419,0.000418289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008364601,"about_ca_system_score_gemma":0.0006255482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007076005,"about_ca_topic_score_gemma":0.00151107,"domain_scores_codex":[0.9995497,0.0001812203,0.00003107714,0.000115264,0.00003517396,0.00008757065],"domain_scores_gemma":[0.9993911,0.0001280261,0.0001766386,0.00006519467,0.00002039867,0.0002186746],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9110137,0.00806804,0.006204689,0.0003786937,0.001066941,0.0001287598,0.0001439568,0.001598839,0.0107627,0.0001414931,0.001118502,0.05937378],"study_design_scores_gemma":[0.4817697,0.4723742,0.03536559,0.00009018005,0.001082326,0.0003023056,0.00009702249,0.001806996,0.003878112,0.0004252958,0.002765154,0.00004308419],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965265,0.001344324,0.0002204278,0.00009744579,0.00004278206,0.0003864862,0.0004792815,0.00002734918,0.0008754141],"genre_scores_gemma":[0.9979734,0.0004346044,0.0002578124,0.0001227454,0.00004396095,0.000240466,0.0004947041,0.000006120858,0.0004261457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002501593,"threshold_uncertainty_score":0.008368731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1105968194228814,"score_gpt":0.4814863051551418,"score_spread":0.3708894857322604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}